Garcia-Recio S - Search Results

1

The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.

Muñoz M, González-Ortega A, Salinas-Martín MV, Carranza A, Garcia-Recio S, Almendro V, Coveñas R. Muñoz M, et al. Int J Oncol. 2014 Oct;45(4):1658-72. doi: 10.3892/ijo.2014.2565. Epub 2014 Jul 28. Int J Oncol. 2014. PMID: 25175857

2

Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.

Mayordomo C, García-Recio S, Ametller E, Fernández-Nogueira P, Pastor-Arroyo EM, Vinyals L, Casas I, Gascón P, Almendro V. Mayordomo C, et al. J Cell Physiol. 2012 Apr;227(4):1358-66. doi: 10.1002/jcp.22848. J Cell Physiol. 2012. PMID: 21604273

3

The Transmodulation of HER2 and EGFR by Substance P in Breast Cancer Cells Requires c-Src and Metalloproteinase Activation.

Garcia-Recio S, Pastor-Arroyo EM, Marín-Aguilera M, Almendro V, Gascón P. Garcia-Recio S, et al. PLoS One. 2015 Jun 26;10(6):e0129661. doi: 10.1371/journal.pone.0129661. eCollection 2015. PLoS One. 2015. PMID: 26114632 Free PMC article.

4

Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death.

Ametller E, García-Recio S, Pastor-Arroyo EM, Callejo G, Carbó N, Gascón P, Almendro V. Ametller E, et al. Cancer Biol Ther. 2011 Jan 1;11(1):4-13. doi: 10.4161/cbt.11.1.13672. Epub 2011 Jan 1. Cancer Biol Ther. 2011. PMID: 20980803

5

Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer.

Garcia-Recio S, Fuster G, Fernandez-Nogueira P, Pastor-Arroyo EM, Park SY, Mayordomo C, Ametller E, Mancino M, Gonzalez-Farre X, Russnes HG, Engel P, Costamagna D, Fernandez PL, Gascón P, Almendro V. Garcia-Recio S, et al. Cancer Res. 2013 Nov 1;73(21):6424-34. doi: 10.1158/0008-5472.CAN-12-4573. Epub 2013 Sep 12. Cancer Res. 2013. PMID: 24030979 Free article.

6

Tyrosine kinase receptor transactivation associated to G protein-coupled receptors.

Almendro V, García-Recio S, Gascón P. Almendro V, et al. Curr Drug Targets. 2010 Sep;11(9):1169-80. doi: 10.2174/138945010792006807. Curr Drug Targets. 2010. PMID: 20450475 Review.

7

The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin.

Almendro V, Ametller E, García-Recio S, Collazo O, Casas I, Augé JM, Maurel J, Gascón P. Almendro V, et al. PLoS One. 2009;4(3):e4728. doi: 10.1371/journal.pone.0004728. Epub 2009 Mar 6. PLoS One. 2009. PMID: 19266094 Free PMC article.

8

Tumor promoting effects of CD95 signaling in chemoresistant cells.

Ametller E, García-Recio S, Costamagna D, Mayordomo C, Fernández-Nogueira P, Carbó N, Pastor-Arroyo EM, Gascón P, Almendro V. Ametller E, et al. Mol Cancer. 2010 Jun 23;9:161. doi: 10.1186/1476-4598-9-161. Mol Cancer. 2010. PMID: 20573240 Free PMC article.

9

Biological and Pharmacological Aspects of the NK1-Receptor.

Garcia-Recio S, Gascón P. Garcia-Recio S, et al. Biomed Res Int. 2015;2015:495704. doi: 10.1155/2015/495704. Epub 2015 Sep 3. Biomed Res Int. 2015. PMID: 26421291 Free PMC article. Review.

10

FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.

Garcia-Recio S, Thennavan A, East MP, Parker JS, Cejalvo JM, Garay JP, Hollern DP, He X, Mott KR, Galván P, Fan C, Selitsky SR, Coffey AR, Marron D, Brasó-Maristany F, Burgués O, Albanell J, Rojo F, Lluch A, de Dueñas EM, Rosen JM, Johnson GL, Carey LA, Prat A, Perou CM. Garcia-Recio S, et al. J Clin Invest. 2020 Sep 1;130(9):4871-4887. doi: 10.1172/JCI130323. J Clin Invest. 2020. PMID: 32573490 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

27 results

Search Page